✨ Free AI Report
Barinthus Biotherapeutics plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview Barinthus Biotherapeutics plc
Research Preview

Barinthus Biotherapeutics plc: Business Overview, Financials & Competitive Analysis

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies to treat autoimmune and inflammatory diseases. The company is undergoing a transformational merger with C...

Analyst-debate audio for Barinthus Biotherapeutics plc

AskCyborg analysts argue the bull and bear cases for Barinthus Biotherapeutics plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Barinthus Biotherapeutics plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
5/ 10Mixed

Cyborg Score thesis

Transformative merger combining diabetes and celiac disease expertise with potential to de-risk immunology pipeline, but...

Read the full analyst-debate transcript →
Industry Clinical-Stage Biopharmaceuticals - Immunotherapy & Autoimmune Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Barinthus Biotherapeutics plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Barinthus Biotherapeutics plc Overview

Pro stress-test →

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies to treat autoimmune and inflammatory diseases. The company is undergoing a transformational merger with Clywedog Therapeutics, expected to close in H1 2026, positioning itself to target Type 1/2 diabetes and celiac disease with a focused pipeline of clinical-stage assets.

Strategic Profile

Pro stress-test →

The company leverages two proprietary platform technologies—viral vector-based (ChAdOx/MVA) and synthetic SNAP-Tolerance Immunotherapy (SNAP-TI)—to develop antigen-specific immune tolerance therapies. With $87.8M in cash and runway extending into 2027, Barinthus is advancing lead candidate VTP-1000 in celiac disease with Phase 1 data expected in Q4 2025, while also pursuing partnerships to monetize its broader portfolio.

Competitive Landscape

Pro stress-test →

Barinthus competes in the clinical-stage immunotherapy space against Inovio Pharmaceuticals, VBI Vaccines, uniQure, Alaunos Therapeutics, and Beam Therapeutics. Differentiation lies in its SNAP-TI synthetic platform enabling antigen-specific immune tolerance—a less crowded mechanism versus checkpoint inhibitors and CAR-T approaches dominating the cancer immunotherapy market.

Industry Context

Barinthus Biotherapeutics plc operates in Clinical-Stage Biopharmaceuticals - Immunotherapy & Autoimmune Diseases.

Key facts

Founded: 2016 · Headquarters: Didcot, United Kingdom · Revenue: $15.0M · Market cap: $24.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Barinthus Biotherapeutics plc.

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when Barinthus Biotherapeutics plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Inovio VaccinesDNA immunotherapy platform for infectious disease and oncology→VBI VaccinesTherapeutic vaccines using eVLP platform technology→CART TherapiesBase editing platform for genetic disease treatment→

Compare Barinthus Biotherapeutics plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Barinthus Biotherapeutics plc operates in Clinical-Stage Biopharmaceuticals - Immunotherapy & Autoimmune Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Clinical-Stage Biopharmaceuticals - Immunotherapy & Autoimmune Diseases research →
NEW · MCP server

Ask your AI assistant about Barinthus Biotherapeutics plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Barinthus Biotherapeutics plc and its top competitor on Cyborg Score”
“What did Barinthus Biotherapeutics plc do this quarter?”
“Is Barinthus Biotherapeutics plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Barinthus Biotherapeutics plc do?+
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapies to treat autoimmune and inflammatory diseases. The company is undergoing a transformational merger with C...
What is Barinthus Biotherapeutics plc's Cyborg Score?+
Barinthus Biotherapeutics plc has a Cyborg Score of 5/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Barinthus Biotherapeutics plc's main competitors?+
Named competitors include Inovio Vaccines, VBI Vaccines, CART Therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full Barinthus Biotherapeutics plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Barinthus Biotherapeutics plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Barinthus Biotherapeutics plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.